An Integrative Model for Palliative Care in End-Stage Liver Disease
Study Details
Study Description
Brief Summary
The purpose of this research study is to understand the impact of palliative care in ESLD on quality of life, emergency room or hospital visits, and on care provider burden, and to work to develop the best way to provide palliative care in ESLD.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
Patients with end-stage liver disease (ESLD) have multiple symptoms that impact their quality of life and result in more emergency room and hospital visits. Palliative care is a medical model that can help alleviate pain and suffering and reduce need for urgent medical care and can do so while continuing other appropriate medical care. While palliative care consults are used in those with ESLD, despite the pain and suffering that accompanies ESLD, palliative care is often used too little and too late.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| End Stage Liver Disease (ESLD) Patients with ESLD |
Other: Standard of care including palliative care
Usual care includes laboratory evaluations, imaging, and certain procedures and medications. In some cases of patients undergoing transplant evaluation, usual care will also include multiple visits with members of the liver transplant team. A palliative care consult will also be part of standard of care. The primary goal of the palliative care consult is not to arrange hospice (though that can be done in appropriate situations) but to identify and try to address the impacts of the disease and its symptoms on patient's life.
|
Outcome Measures
Primary Outcome Measures
- Change in symptom intensity [Up to 60 days]
Edmonton Symptom Assessment System (ESAS) - participants rate the intensity of common symptoms on 0-10 scale with 0= no symptom and 10=worst symptom imaginable. Scores range from 0 to 90 with higher scores indicating worse symptoms.
- Change in liver disease QOL [Up to 60 days]
Short-Form Liver Disease QOL - The SF-LDQOL includes 36 disease-targeted items representing nine domains: symptoms of liver disease, effects of liver disease, memory/concentration, sleep, hopelessness, distress, loneliness, stigma of liver disease and sexual problems. The minimum and maximum values of the scale are 0-100 with higher scores indicating better QOL.
- Change in depression [Up to 60 days]
Patient Health Questionnaire 9 (PHQ-9) is a self-report instrument which assesses depression. Scores range from 0 to 27 with higher scores indicating worse depression.
- Change in anxiety [Up to 60 days]
Generalized Anxiety Disorder 7-Item Scale (GAD-7) is a self-report instrument which assesses anxiety. Scores range from 0 to 21 with higher scores indicating greater anxiety.
- Change in perform ordinary tasks [Up to 60 days]
The Karnofsky Performance Status will be used to assess participants ability to perform ordinary tasks. Scores range from 0 to 100 with higher scores indicating greater ability.
- Change in caregiver burden [Up to 60 days]
The Zarit Burden Interview
- Hospital readmissions and/or Emergency room (ER) visits [60 days]
Number of participants with ER visits or who are readmitted to the hospital during the study period
Eligibility Criteria
Criteria
Inclusion Criteria:
Primary participant:
-
admission for decompensated cirrhosis, age ≥ 18
-
willingness to sign consent
-
able to read and understand English
-
presence of decompensated cirrhosis with portal hypertension (jaundice, ascites, HE, hepatohydrothorax, AKI, HRS and/or variceal bleeding) or HCC
Caregiver:
-
identified as the primary caregiver of the participant
-
age ≥ 18
-
willingness to sign consent
-
able to read and understand English
Exclusion Criteria:
Primary participant:
-
prior liver transplant
-
lack of capacity to provide informed consent (in the judgement of the investigator)
-
already in receipt of palliative or hospice care
-
those who are likely to receive a LT during the index admission
Caregiver:
• none
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Virginia Commonwealth University | Richmond | Virginia | United States | 23298 |
Sponsors and Collaborators
- Virginia Commonwealth University
Investigators
- Principal Investigator: Joel Wedd, MD, MPH, Virginia Commonwealth University
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- HM20023178